This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ICo Therapeutics Announces Second Quarter 2013 Financial Results

VANCOUVER, Aug. 26, 2013 /PRNewswire/ - iCo Therapeutics (TSX-V: ICO), today reported financial results for the quarter ended June 30, 2013. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS").

"The quarter was strong both operationally and financially," said Andrew Rae, iCo's President & CEO.  "We completed the enrollment of the phase two iDEAL study initiating the countdown to our primary endpoint for the study - eight month visual acuity as compared to baseline.  This is a very large phase two study in diabetic macular edema and to date has demonstrated a strong safety profile, with no drug-related serious adverse events. In support of this study we also strengthened our balance sheet through an overnight marketed equity offering for gross proceeds of three million eight hundred thousand dollars."

First Quarter 2013 Financial & Operational Highlights
  • Completed enrollment of the Phase 2 iDEAL study evaluating the efficacy and safety after repeated injections of iCo-007 in patients with Diabetic Macular Edema (DME).  The study to date has demonstrated a strong safety profile with no drug-related serious adverse events.
  • Completed overnight marketed offering of 9,655,771 units for aggregate gross proceeds of $3,379,519.90.

Summary First Quarter 2013 Results iCo incurred a net and comprehensive loss of $2,886,831 for the six months ended June 30, 2013, compared to a net and comprehensive loss of $1,431,634 for the same period last year.  The increase was driven primarily by costs associated with the Phase 2 clinical trial, as well as share based compensation. This was partially offset by the gain on the IMMUNE shares in other investments.

Research and development expenses were $2,189,830 for the six months ended June 30, 2013 compared to $739,081 for the same period last year, representing an increase of $1,450,749. This increase in research and development expenses is due to higher costs relating to the iDEAL Phase 2 clinical trial.

General and administrative expenses primarily comprise salaries, stock based compensation and benefits for company employees not involved in research and development, professional fees such as legal and accounting expenses, and expenses related to office overheads. For the six months ended June 30, 2013 general and administrative expenses were $1,166,480 compared to $681,293 for the six months ending June 30, 2012, representing an increase of $485,187.  The higher expenses are due to increased stock based compensation and professional fees.

We believe the Company has sufficient personnel to manage both its research and development and public company activities and do not anticipate any increase in staffing in the foreseeable future.  Accordingly, we believe that general and administrative expenses should remain at current levels in the foreseeable future.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.21 -0.44%
FB $117.80 -0.22%
GOOG $701.26 0.80%
TSLA $211.34 -5.00%
YHOO $36.94 2.61%


Chart of I:DJI
DOW 17,660.71 +9.45 0.05%
S&P 500 2,050.63 -0.49 -0.02%
NASDAQ 4,717.0940 -8.5450 -0.18%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs